Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cyanotech Corporation Announces Conversion of $1.25 Million of Debentures to Equity.


Business Editors/Health/Medical Writers

KAILUA KONA, Hawaii--(BUSINESS WIRE)--Dec. 11, 2003

Cyanotech Corporation (Nasdaq:CYAN), a world leader in producing high-value natural products from microalgae, today announced that the holder of a $1,250,000 principal amount convertible debenture Convertible Debenture

Any type of debenture that can be converted into some other security.

Notes:
For example, a convertible bond can be converted into stock.
 has voluntarily converted the debt to 1,923,076 shares of the Company's common stock. In addition to reducing overall debt and increasing the company's net equity, this conversion will decrease future quarterly interest expense by $31,000.

About Cyanotech

Cyanotech Corporation, a world leader in microalgal technology, produces high-value natural products from microalgae and is the world's largest commercial producer of natural astaxanthin (pronounced "asta-zan-thin") from microalgae. Products include BioAstin(R) natural astaxanthin, a powerful antioxidant antioxidant, substance that prevents or slows the breakdown of another substance by oxygen. Synthetic and natural antioxidants are used to slow the deterioration of gasoline and rubber, and such antioxidants as vitamin C (ascorbic acid), butylated hydroxytoluene  with expanding applications as a human nutraceutical; NatuRose(R) natural astaxanthin for the aquaculture aquaculture, the raising and harvesting of fresh- and saltwater plants and animals. The most economically important form of aquaculture is fish farming, an industry that accounts for an ever increasing share of world fisheries production.  and animal feed industries; Spirulina spirulina

Any cyanobacteria in the genus Spirulina. A traditional food source in parts of Africa and Mexico, spirulina is an exceptionally rich source of vitamins, minerals, and protein, and one of the few nonanimal sources of vitamin B12.
 Pacifica(R), a nutrient-rich dietary supplement; and phycobiliproteins, which are fluorescent pigments used in the immunological diagnostics market. Spirulina Pacifica and BioAstin are sold directly online through the Company's website, www.nutrex-hawaii.com, as well as through resellers in over 30 countries worldwide. Technical information for the Company's phycobiliproteins products is available at www.phycobiliprotein.com. Corporate data and other product information are available at www.cyanotech.com.

"Safe Harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995

Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, forecasts of sales in future periods, changes in sales levels to our largest customers, weather patterns, risks associated with the acceptance of new products, competition, foreign exchange fluctuations, government regulation, and other factors more fully detailed in the Company's recent Form 10-Q Form 10-Q

See 10-Q.
 and annual form 10-K filings with the Securities and Exchange Commission.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 11, 2003
Words:318
Previous Article:IntelliGolf 7.0 Ships with GPS and Bluetooth.
Next Article:Regal Entertainment Group Announces New Theatre for Lacey - Olympia, WA.
Topics:



Related Articles
Cyanotech Completes Private Financing for $1.1 Million.
Cyanotech Reports Financial Results for the 4th Quarter and Fiscal 2000; 4th Quarter Sales Increase 28%, Net Loss Narrowed.
Cyanotech Reports First Quarter Income from Operations with 35% Increase in Sales; Net Loss Is Reduced to $22,000 from a Net Loss of $527,000.
Cyanotech Reports $2.1 Million of Preferred Stock Dividends No Longer Payable.
Cyanotech Reports Third Quarter Fiscal 2001 Financial Results; Initiation of Second Clinical Trial for BioAstin Announced.
Cyanotech Reports First Quarter Fiscal 2003 Financial Results.
Cyanotech Reports Second Quarter Fiscal 2003 Financial Results.
Cyanotech Corporation Reports Second Quarter Fiscal 2004 Financial Results; Company Reports Quarter to Quarter Sales Increase of 17%.
Cyanotech Corporation Reports Third Quarter Fiscal 2004 Financial Results; Company Reports Net Income of $109,000 on Increased Sales and Improved...
Cyanotech Corporation Reports First Quarter Fiscal 2005 Financial Results; Reports Net Income of $113,000.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles